Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Angie Molina
Institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra,
Centro de Investigación Médica Aplicada
Observed institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra,
Centro de Investigación Médica Aplicada,
Universidad de Navarra
ORCID:
0000-0002-8572-642X
Observed ORCID:
0000-0002-8572-642X
OpenAlex ID:
A5050004212
Gene Therapy for Acquired and Genetic Cholestasis
2022
·
Javier Martínez-García
, Angie Molina
, et al.
·
Biomedicines
·
15
PDF
A minimal bile salt excretory pump promoter allows bile acid-driven physiological regulation of transgene expression from a gene therapy vector
2022
·
Javier Martínez-García
, Manuela Molina
, et al.
·
Cell & Bioscience
·
9
PDF
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
·
Clinical Cancer Research
·
5
Liver-directed gene therapy results in amelioration of progressive familial intrahepatic cholestasis type 2 in mice
2026
·
Angie Molina
, Laia Trigueros-Motos
, et al.
·
Hepatology Communications
·
1
Antibody–Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors
2026
·
Gabriel Gomis
, Claudia Herrero
, et al.
·
Cancer Research
·
1
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment
2026
·
Elixabet Bolaños
, Lorena Cañas-Zabala
, et al.
·
The Journal of Experimental Medicine
·
1
PDF
1123 TNFR1 expression on cancer cells is critical for immune escape shaping an immunosuppressive tumor microenvironment
2026
·
Lorena Cañas Zabala
, Elixabet Bolaños
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Figure S5 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Data from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Supplementary Appendix from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Gene Therapy for Cerebrotendinous Xanthomatosis (CTX)
2025
·
Rubén Hernández-Alcoceba
, Angie Molina
, et al.
·
Springer eBooks
COVID-19 mRNA vaccines are effective at stopping a nosy virus
2025
·
Uxue Beloki
, Laura Salaberry
, et al.
·
Molecular Therapy — Nucleic Acids
Show more works
View as search
Works count:
20
Citation count:
32
H-index:
3
I10-index:
1
Year
Topic
Type